AMAG Pharmaceuticals’ Abbreviated NDA for Progestin Injection Receives FDA Approval

AMAG Pharmaceuticals (AMAG) disclosed in a regulatory filing late Monday that the U.S. Food & Drug Administration (FDA) has approved the the abbreviated new drug application for Hydroxyprogesterone Caproate Injection USP, 250 mg/mL (1.25 g/5 mL vials).

The NDA was initially submitted by McGuff Pharmaceuticals, Inc. in 2009.

AMAg also said it has obtained, through a Freedom of Information Act request, the package insert for this product.

Hydroxyprogesterone Caproate is a man-made hormone of progestin. It is used in pregnant women to help lower the risk of giving birth too early (preterm birth or giving birth less than 37 weeks of pregnancy).

Shares are up 0.02% at $41.35 in the after hours session, with a 52-week range of $29.76 – $77.73.

Companies: AMAG Pharmaceuticals, Inc.
Price: 41.35 Price Change: +0.01 Percent Change: +0.02

Previous articleBiomed Realty Trust Exploring Sale
Next articleVeritiv Files $200 Mln Mixed Shelf Offering
John Smith
An engineer by degree and blogger by choice. Interested in writing the latest updates happening around the world. Loves to binge watch tv-series and movies.


Please enter your comment!
Please enter your name here